-
nor-Binaltorphimine Dihydrochloride in Pain Circuits
2026-09-09
A mechanistic guide to using nor-Binaltorphimine dihydrochloride to interrogate spinal κ-opioid receptor signaling within brain-to-spinal circuits that regulate the laterality and persistence of mechanical allodynia.
-
S Tag Peptide (A6007): Practical Workflow Guide
2026-09-08
S Tag Peptide provides a compact S-peptide fusion tag for recombinant protein detection, antibody-based purification workflows, and protein solubility improvement. This guide explains construct design, aqueous or DMSO handling, QC, and limitations; it is not intended for ethanol-based workflows or independent enzymatic activity.
-
MDM1, p53, and Chemoradiotherapy Sensitivity in CRC
2026-09-08
The reference study identifies MDM1 as more than a response-associated biomarker: it functions through a YBX1–TP53 regulatory axis to influence apoptosis and colorectal cancer chemoradiotherapy sensitivity. Its combined cellular, transcriptomic, mechanistic, and xenograft evidence supports MDM1 as a candidate predictive marker while highlighting apoptosis modulation as a possible strategy for resistant disease.
-
Latrunculin A for Actin Dynamics Workflows
2026-09-07
Latrunculin A enables controlled, reversible actin perturbation for rapid cytoskeleton disaggregation, morphology assays, and mechanobiology experiments. This workflow connects dose-and-washout design with stiffness-dependent DRG axon regeneration research, helping investigators separate actin-driven phenotypes from upstream mechanical signaling.
-
Afatinib (BIBW 2992) for Cancer Biology Research
2026-09-05
Afatinib, also known as BIBW 2992, is an irreversible ErbB-family kinase inhibitor used to interrogate EGFR, HER2, and HER4 signaling. Its research value is strongest when mutation status, stromal context, exposure conditions, and appropriate pharmacodynamic controls are measured together.
-
NHS-Biotin: A Translational Readout for Nanobodies
2026-09-05
Multimeric nanobody engineering can increase avidity and functional versatility, but translation depends on reliable methods to confirm assembly, accessibility, and recovery. This thought-leadership article explains how NHS-Biotin can serve as a low-profile analytical and purification handle alongside peptidisc-assisted protein clustering.
-
Docosahexaenoic Acid: From Lipid Maps to Assays
2026-09-04
Docosahexaenoic Acid (DHA) is not simply an antioxidant supplement; it is a membrane-active lipid that links hippocampal metabolism to synaptic function. This article translates spatial metabolomics findings into better assay design, controls, and interpretation for neuroprotection research.
-
Streptavidin – Cy5 in Breast Cancer Assays
2026-09-04
Streptavidin – Cy5 converts biotinylated antibodies, proteins, and nucleic acid probes into sensitive far-red readouts for imaging and flow cytometry. This guide connects the reagent to USP42–JNK/p38 apoptosis research with practical workflows, assay controls, and troubleshooting strategies.
-
DMH1 Workflows for BMP and Organoid Research
2026-09-03
DMH1 provides a practical route to selectively modulate ALK2-dependent BMP signaling in organoid and cancer workflows. This guide connects pathway readouts with assay-ready handling, dose-finding, and troubleshooting strategies for reproducible research.
-
Protease Inhibitor Cocktail: K4003 Guide
2026-09-03
A scenario-driven laboratory guide to using Protease Inhibitor Cocktail (100X H₂O, EDTA Plus), SKU K4003, for preserving protein measurements after cell or tissue lysis. It explains assay compatibility, EDTA-related limitations, workflow optimization, interpretation, and practical vendor-selection criteria.
-
HRP Rabbit Anti-Goat IgG (H+L) Antibody Workflow
2026-09-02
Build sensitive, reproducible workflows for detecting goat primary antibodies across western blotting, ELISA, dot blotting, and tissue staining. This guide connects practical HRP assay optimization with validation needs highlighted by localized p21 mRNA–LNP research in bladder cancer.
-
VX-702 and the Hidden Kinetics of p38α MAPK
2026-09-02
VX-702 is a selective p38α MAPK inhibitor whose assay behavior depends on ATP competition, activation-loop conformation, and phosphatase-driven signal decay. This guide translates emerging structural biology into better experimental decisions across inflammation, platelet, and cardiovascular research.
-
NF 449 for P2X1 Platelet Assays
2026-09-01
NF 449 is a high-potency purinergic receptor antagonist for dissecting ATP-driven P2X1 signaling from P2Y1- and P2Y12-mediated platelet responses. This guide translates the reference findings into practical aggregation, calcium-flux, collagen-response, and thrombosis workflows, with troubleshooting strategies for selectivity and assay variability.
-
CXCR4 Theranostics in Lymphoma: Evidence and Limits
2026-09-01
This 2026 review frames CXCR4 as a theranostic target in lymphoma by linking receptor-directed PET and SPECT imaging with peptide, radioligand, small-molecule, and antibody therapies. Its main contribution is an integrated interpretation of target biology, imaging specificity, treatment selection, and translational barriers such as physiological uptake and compensatory CXCR7 signaling.
-
Methyl-β-cyclodextrin Workflow Guide
2026-08-31
Methyl-β-cyclodextrin (SKU C6939) provides a controllable way to extract cholesterol and selected lipids from cellular membranes for studies of membrane organization, fluidity, and cholesterol-dependent signaling. It is intended for biochemical and cell membrane research only, not for diagnostic, therapeutic, or medical use, and working concentrations and exposure conditions should be optimized empirically because no directly matched paper evidence is supplied.